Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Change in Accured Expenses (2016 - 2025)

Ultragenyx Pharmaceutical (RARE) has disclosed Change in Accured Expenses for 10 consecutive years, with $37.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Change in Accured Expenses fell 20.22% to $37.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $24.0 million, a 48.94% decrease, with the full-year FY2025 number at $24.0 million, down 48.94% from a year prior.
  • Change in Accured Expenses was $37.0 million for Q4 2025 at Ultragenyx Pharmaceutical, down from $45.1 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $57.4 million in Q2 2022 to a low of -$48.5 million in Q1 2025.
  • A 5-year average of $9.1 million and a median of $11.9 million in 2021 define the central range for Change in Accured Expenses.
  • Biggest YoY gain for Change in Accured Expenses was 450.03% in 2021; the steepest drop was 338.45% in 2021.
  • Ultragenyx Pharmaceutical's Change in Accured Expenses stood at $30.4 million in 2021, then decreased by 9.75% to $27.4 million in 2022, then plummeted by 44.49% to $15.2 million in 2023, then skyrocketed by 204.72% to $46.4 million in 2024, then dropped by 20.22% to $37.0 million in 2025.
  • Per Business Quant, the three most recent readings for RARE's Change in Accured Expenses are $37.0 million (Q4 2025), $45.1 million (Q3 2025), and -$9.7 million (Q2 2025).